Archynetys Live news trend intelligence
▲ Peaking Health

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

India has approved Takeda's Qdenga, marking the country's first-ever authorized vaccine against dengue.

7sources
8articles
5velocity
+89%since first seen
6h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

The Drug Controller General of India (DCGI) has cleared the use of Qdenga, a vaccine developed by Japanese drugmaker Takeda. The vaccine is approved for individuals between the ages of 4 and 60.

Coverage from Reuters, NDTV, and The Indian Express highlights the vaccine's status as a national first. The Hindu and The Times of India emphasize the specific age eligibility and the medical complexities surrounding the four virus strains and the challenge of achieving immunity.

Future developments depend on the rollout of the vaccine and further explanations regarding dosing and eligibility as outlined in reports by NDTV.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6h ago.

Quick answers

Who developed the vaccine?

The vaccine, named Qdenga, was developed by the Japanese drugmaker Takeda.

Who is eligible to receive the vaccine in India?

The vaccine is approved for individuals aged 4 to 60 years.

Which regulatory body approved the vaccine?

The vaccine was cleared by the DCGI.

Coverage (8)

Topics

Related trends